TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07759362: Study to Assess KN3835 in the Treatment of Flexible/Semi-Flexible Hammertoe (HMT)

Sponsor: Endo USA Inc., a Keenova Therapeutics Company · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 554 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07759362 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07759362 Rescue Dossier →